KYKOF: AI 评分 57/100 — AI 分析 (4月 2026)

Kyowa Kirin Co., Ltd. is a global specialty pharmaceutical company focused on oncology, nephrology, central nervous system, and immunology. The company develops and markets a range of pharmaceutical products, including treatments for breakthrough cancer pain, allergies, hypertension, and various other diseases.

Key Facts: AI Score: 57/100 Sector: Healthcare

公司概况

概要：

Kyowa Kirin Co., Ltd. is a global pharmaceutical company specializing in oncology, nephrology, CNS, and immunology, offering treatments like Crysvita and Romiplate. With a 13.5% profit margin and 74.2% gross margin, the company operates as a subsidiary of Kirin Holdings, focusing on innovative therapies and strategic collaborations within the healthcare sector.

KYKOF是做什么的？

Kyowa Kirin Co., Ltd., established in 1949 and headquartered in Tokyo, Japan, is a global specialty pharmaceutical company dedicated to discovering and developing innovative medicines. Originally known as Kyowa Hakko Kirin Co., Ltd., the company rebranded in June 2019 to Kyowa Kirin Co., Ltd. The company focuses on four therapeutic areas: oncology, nephrology, central nervous system (CNS), and immunology. Its diverse portfolio includes products like Crysvita, a recombinant human monoclonal antibody used for hypophosphatemia, and Romiplate/Nplate, a genetically recombinant protein for platelet production. Other key products include ABSTRAL for breakthrough cancer pain, ALLELOCK for allergies, and CONIEL for hypertension and angina pectoris. Kyowa Kirin also develops treatments for chemotherapy-induced febrile neutropenia, acute lymphoblastic leukemia, psoriasis, opioid-induced constipation, and Parkinson's disease. The company has a strategic agreement with Amgen Inc. to develop and commercialize KHK4083 for atopic dermatitis. As a subsidiary of Kirin Holdings Company, Limited, Kyowa Kirin leverages its research and development capabilities to address unmet medical needs worldwide.

KYKOF的投资论点是什么？

Kyowa Kirin Co., Ltd. presents a compelling investment case based on its focus on specialized therapeutic areas and a robust product portfolio. With a P/E ratio of 18.79 and a dividend yield of 2.58%, the company demonstrates financial stability and shareholder returns. Key value drivers include the continued commercial success of Crysvita and Romiplate, as well as the potential approval and launch of KHK4083 in collaboration with Amgen. Growth catalysts include expanding into new geographic markets and indications, and strategic partnerships. Potential risks include regulatory challenges, competition from biosimilars, and patent expirations. The company's 13.5% profit margin and 74.2% gross margin indicate efficient operations and strong pricing power.

KYKOF在哪个行业运营？

Kyowa Kirin operates in the global pharmaceutical industry, which is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and technological advancements in drug discovery. Key trends include the rise of personalized medicine, the growing importance of biologics, and the increasing focus on rare diseases. Kyowa Kirin competes with major pharmaceutical companies, including ESAIY (Eisai Co., Ltd.) and GIFLF (Gilead Sciences, Inc.), focusing on specialized therapeutic areas to differentiate itself.

Drug Manufacturers - General

Healthcare

KYKOF有哪些增长机遇？

Growth opportunity 1: Expansion of Crysvita into new markets and indications represents a significant growth opportunity. Crysvita, used for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, has demonstrated strong sales growth. Expanding its availability to additional countries and exploring new indications, such as other phosphate-related disorders, could drive further revenue growth. The market for rare bone diseases is estimated to reach $3 billion by 2028, providing a substantial addressable market for Kyowa Kirin.
Growth opportunity 2: The successful development and commercialization of KHK4083 for atopic dermatitis, in collaboration with Amgen, presents a major growth catalyst. Atopic dermatitis is a chronic inflammatory skin disease with a high unmet need, and the market for atopic dermatitis treatments is projected to reach $12 billion by 2027. Positive Phase 3 trial results and subsequent regulatory approvals could significantly boost Kyowa Kirin's revenue and market share.
Growth opportunity 3: Strategic partnerships and acquisitions can enhance Kyowa Kirin's product portfolio and expand its geographic reach. Collaborating with other pharmaceutical companies or acquiring promising drug candidates in its core therapeutic areas can accelerate growth and diversify its revenue streams. The company could target companies with innovative technologies or complementary product lines to strengthen its competitive position. The pharmaceutical M&A market is expected to remain active, providing opportunities for Kyowa Kirin to pursue strategic deals.
Growth opportunity 4: Focusing on the development of novel biologics and biosimilars can drive long-term growth. Biologics are complex drugs derived from living organisms, and they often command premium prices. Developing biosimilars, which are similar versions of existing biologics, can provide a more affordable alternative and capture market share. The global biosimilars market is projected to reach $35 billion by 2025, offering a significant opportunity for Kyowa Kirin.
Growth opportunity 5: Expanding into emerging markets, such as China and India, can fuel growth and diversify Kyowa Kirin's revenue base. These markets have large populations, increasing healthcare spending, and a growing demand for innovative medicines. Navigating the regulatory landscape and establishing a strong presence in these markets will be crucial for success. The pharmaceutical market in emerging markets is expected to grow at a faster rate than in developed markets, providing a significant growth opportunity for Kyowa Kirin.

Market Cap of $6.50B reflects Kyowa Kirin's significant presence in the pharmaceutical industry.
P/E Ratio of 18.79 indicates a reasonable valuation compared to its earnings.
Profit Margin of 13.5% demonstrates the company's ability to generate profit from its revenue.
Gross Margin of 74.2% showcases efficient production and strong pricing power.
Dividend Yield of 2.58% provides a steady income stream for investors.

KYKOF提供哪些产品和服务？

Develops and markets pharmaceuticals for oncology, nephrology, central nervous system, and immunology.
Offers treatments for breakthrough cancer pain, allergies, hypertension, and other diseases.
Produces recombinant human monoclonal antibodies and genetically recombinant proteins.
Collaborates with other pharmaceutical companies to develop and commercialize new drugs.
Focuses on innovative therapies and addressing unmet medical needs worldwide.
Manufactures and distributes a range of pharmaceutical products globally.

KYKOF如何赚钱？

Develops and manufactures proprietary pharmaceutical products.
Markets and sells these products through its own sales force and distribution network.
Collaborates with other companies for research, development, and commercialization.
Generates revenue through product sales and licensing agreements.

Patients with cancer, kidney disease, neurological disorders, and immune system disorders.
Hospitals and clinics that prescribe and administer Kyowa Kirin's products.
Pharmacies that dispense Kyowa Kirin's medications.
Healthcare providers who recommend and prescribe Kyowa Kirin's treatments.

Proprietary drug formulations and intellectual property protection.
Strong brand recognition and reputation in specialized therapeutic areas.
Established relationships with healthcare providers and key opinion leaders.
Strategic collaborations with other pharmaceutical companies.
High barriers to entry in the pharmaceutical industry due to regulatory requirements and R&D costs.

什么因素可能推动KYKOF股价上涨？

Upcoming: Potential regulatory approval and launch of KHK4083 for atopic dermatitis in collaboration with Amgen.
Ongoing: Continued commercial success of Crysvita in existing and new markets.
Ongoing: Expansion of Romiplate/Nplate into new indications and patient populations.

KYKOF的主要风险是什么？

Potential: Competition from biosimilars and generic drugs could erode market share.
Potential: Regulatory challenges and delays in drug approvals.
Potential: Unfavorable clinical trial results for pipeline products.
Ongoing: Pricing pressures from healthcare payers could impact profitability.
Ongoing: Patent expirations on key products could reduce revenue.

KYKOF的核心优势是什么？

Strong focus on specialized therapeutic areas.
Robust product portfolio with innovative treatments.
Strategic collaborations with other pharmaceutical companies.
Established presence in key markets.

KYKOF的劣势是什么？

Reliance on a limited number of key products.
Exposure to patent expiration risks.
Dependence on collaborations for certain products.
Limited presence in emerging markets compared to larger competitors.

KYKOF有哪些机遇？

Expansion into new geographic markets.
Development of novel biologics and biosimilars.
Acquisition of promising drug candidates.
Increased demand for specialized treatments in its core therapeutic areas.

KYKOF面临哪些威胁？

Competition from biosimilars and generic drugs.
Regulatory challenges and delays.
Pricing pressures from healthcare payers.
Unfavorable clinical trial results.

KYKOF的竞争对手是谁？

Eisai Co., Ltd. — Focuses on neurology and oncology. — (ESAIY)
Eisai Co Ltd — Global pharmaceutical company with a focus on neurology and oncology. — (ESALF)
Gilead Sciences, Inc. — Specializes in antiviral drugs. — (GIFLF)
Gilead Sciences Inc — Focuses on antiviral therapies, particularly for HIV and hepatitis. — (GIFOF)
Merck & Company, Inc. — Diversified pharmaceutical company with a broad range of products. — (MSMKF)

Key Metrics

MoonshotScore: 57/100

Company Profile

CEO: Masashi Miyamoto
Headquarters: Tokyo, JP
Employees: 5,669
Founded: 2012

AI Insight

AI analysis pending for KYKOF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Kyowa Kirin Co., Ltd. do?

Kyowa Kirin Co., Ltd. is a global specialty pharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. The company's primary therapeutic areas include oncology, nephrology, central nervous system (CNS), and immunology. Kyowa Kirin develops and markets a range of pharmaceutical products, including treatments for breakthrough cancer pain, allergies, hypertension, and various other diseases. Its key products include Crysvita, a recombinant human monoclonal antibody, and Romiplate/Nplate, a genetically recombinant protein. The company operates as a subsidiary of Kirin Holdings Company, Limited.

What do analysts say about KYKOF stock?

AI analysis is currently pending for KYKOF, so a summary of analyst consensus is not yet available. Key valuation metrics to consider include the company's P/E ratio of 18.79, profit margin of 13.5%, and dividend yield of 2.58%. Growth considerations include the potential for Crysvita and KHK4083, as well as expansion into new markets and indications. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. Analyst ratings and price targets will be available when the AI analysis is complete.

What are the main risks for KYKOF?

Kyowa Kirin faces several risks, including competition from biosimilars and generic drugs, which could erode market share and pricing power. Regulatory challenges and delays in drug approvals could also impact the company's pipeline and revenue growth. Unfavorable clinical trial results for pipeline products could lead to setbacks and reduced investor confidence. Pricing pressures from healthcare payers could limit profitability. Patent expirations on key products could significantly reduce revenue. Investors should carefully consider these risks before investing in KYKOF.